Provided by Tiger Trade Technology Pte. Ltd.

HUTCHMED

21.580
-0.760-3.40%
Volume:5.81M
Turnover:127.71M
Market Cap:18.82B
PE:41.50
High:23.000
Open:22.340
Low:21.500
Close:22.340
52wk High:26.000
52wk Low:15.570
Shares:872.00M
HK Float Shares:872.00M
Volume Ratio:2.07
T/O Rate:0.67%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.520
ROE:1.46%
ROA:-1.24%
PB:1.90
PE(LYR):41.50
PS:4.37

Loading ...

Hutchmed (China) - to Start Global Phase 1 Development Program in H2 2026

THOMSON REUTERS
·
Sep 03

Hutchmed Licenses KRAS-EGFR Antibody Conjugate HMPL-A830 to GSK for USD 110 Million Upfront

Reuters
·
Sep 03

Hutchmed (China) - Agreement Includes $110 Mln Upfront, up to $1.30 Bln in Milestones, Plus Royalties

THOMSON REUTERS
·
Sep 03

Hutchmed Announces Licensing Agreement with GSK for Kras-Egfr-Antibody Conjugate Cancer Therapy

THOMSON REUTERS
·
Sep 03

Hong Kong Stocks Edge Lower on Monday Amid Middle East Tensions; HUTCHMED Falls 2%

MT Newswires Live
·
Aug 31

Hutchmed Says Savolitinib Plus AstraZeneca’s Tagrisso Extends PFS in China Phase III Sanovo Lung Cancer Trial

Reuters
·
Aug 31

HUTCHMED Sees Positive High Level Results in Lung Cancer Drug Combo Trial

MT Newswires Live
·
Aug 31

Hutchmed (China) - Announces Positive Results from Sanovo China Phase Trial in Nsclc Patients

THOMSON REUTERS
·
Aug 31

Hutchmed Announces Sanovo Trial Demonstrated Significant Progression-Free Survival Benefit of Orpathys® Plus Tagrisso® in Treatment-NaÏVe Patients with Met-Overexpressing Egfr-Mutated Lung Cancer in China

THOMSON REUTERS
·
Aug 31

Sector Update: Health Care Stocks Mixed Pre-Bell Friday

MT Newswires Live
·
Aug 28

Hutchmed (China) Announces NMPA Conditional Approval for ATLED in China

Reuters
·
Aug 28

HUTCHMED's Cholangiocarcinoma Drug Application Gets Conditional Nod in China

MT Newswires Live
·
Aug 28

Hutchmed (China) - Fanregratinib to be Marketed in China as Atled

THOMSON REUTERS
·
Aug 28

Hong Kong Market Movers: Mixue's Revenue Reaches RMB 15.2 Billion in First Half, Global Store Network Expands

Stock News
·
Aug 28

HUTCHMED Secures NMPA Conditional Approval for ATLED® (Fanregratinib) Targeting FGFR2-Altered Intrahepatic Cholangiocarcinoma

Bulletin Express
·
Aug 28

HUTCHMED secures NMPA approval for ATLED to address FGFR2-altered intrahepatic cholangiocarcinoma

Stock News
·
Aug 28

Hutchmed (China) - Announces Nmpa Conditional Approval for Atled (Fantegratinib) in China

THOMSON REUTERS
·
Aug 28

Hutchmed Says China NMPA Approves ATLED for FGFR2-Altered Intrahepatic Cholangiocarcinoma

Reuters
·
Aug 28

Hutchmed Announces Nmpa Approval for Atled® (Fanregratinib) for the Treatment of Patients with Fgfr2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma

THOMSON REUTERS
·
Aug 28

Dow Jones Top Company Headlines at 1 PM ET: Walmart Shares Slump on Weakest Sales Growth in over Six Years | Super ...

Dow Jones
·
Aug 21